The global gestational trophoblastic disease market is expected to grow significantly at a healthy CAGR during the forecast period from 2018 to 2023. Gestational trophoblastic disease (GTD) comprises a group of interrelated ailments that arise from the placental trophoblastic tissue. This can occur after normal or abnormal fertilization and is characterized by a distinct tumor marker, β-subunit of human chorionic gonadotrophin (β HCG).
Increase in risk factors affecting this spectrum of disease is expected to drive the growth of the market. These risk factors include high maternal age, the rise in ectopic pregnancies and excessive smoking. According to the American Lung Association, cigarette smoking kills an estimated 201,770 women annually in the US. Also, the increase in innovations in the field of oncology in anticipated to contribute significantly to the growth in this market. For instance, as on 11th October 2018, Bristol-Myers Squibb Company and Compugen Ltd. announced a clinical collaboration to evaluate therapeutic regimen in advanced solid tumors. Compugen Ltd., being a therapeutic discovery company, consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations.
Moreover, high risk of recurrence of the tumors, even after single or multi-agent chemotherapy and difficulty in diagnosing the types of hydatidiform moles may hamper the market growth. Also, mismanagement of the disease with unclear or no guidelines in different regions may curb the growth of gestational trophoblastic disease during the assessment period. Some of the forms of the gestational trophoblastic disease start to show symptoms only after it reaches stage III. At this stage, it might have already spread to other parts of the body. According to the American Society of Clinical Oncology (ASCO), about 35% of women with placental-site trophoblastic tumor have had the cancer spread before it was diagnosed.
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6558
The global gestational trophoblastic disease market has been segmented into type, treatment, and end user.
The market, on the basis of type, has been segmented into a hydatidiform mole, choriocarcinoma, placental-site trophoblastic tumor, epithelioid trophoblastic tumor, and others.
The market, based on the hydatidiform mole, has been further segmented into a complete, partial and invasive mole. The market, based on hydatidiform mole is expected to hold the largest share as it is the most common form of the gestational trophoblastic disease, whereas choriocarcinoma is projected to be the fastest-growing market as the incidence rate of this form is increasing steadily according to a journal published by National Center for Biotechnology Information.
The market, by treatment, has been segmented into surgery, chemotherapy, suction dilation and curettage (D&C), and radiation therapy.
the market, based on surgery, has been sub-segmented into an abdominal hysterectomy and vaginal hysterectomy.
The market, by end user, has been segmented into hospital and clinics, diagnostic centers, and others.
The market has been segmented regionally into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The gestational trophoblastic disease market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European gestational trophoblastic disease market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The gestational trophoblastic disease market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The gestational trophoblastic disease market in the Middle East & Africa has been segmented into the Middle East and Africa.
Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Pfizer Inc., Bristol-Myers Squibb Company, Antares Pharma, Mylan N.V., Novartis AG, BP Pharmaceuticals Laboratories Company, Fresenius Kabi AG, Accord Healthcare, Inc., Eli Lilly and Company, Sanofi, Bayer AG, Amgen Inc. and Merck are some of the key players in the global gestational trophoblastic disease market.
Regional Market Summary
Global Gestational Trophoblastic Disease Market Share (%), by Region, 2017
Source: World Health Organization (WHO), Centers for Disease Control and Prevention (CDC)
Geographically, the Americas is projected to dominate the global gestational trophoblastic disease market owing to an increased awareness about the disease and favorable reimbursement scenario. Also, the rise in a number of marketing approvals, as well as product approvals in the field of oncology drive the market growth.
Europe is expected to hold the second largest position in the global gestational trophoblastic disease market. The market growth in this region is attributed to the availability of funds for research and an increasing healthcare expenditure.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population and continuously developing economies.
On the other hand, the Middle East and Africa has the least share of the market. This is due to the stringent government regulations and lack of technical expertise in the treatment of the disease.
Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/gestational-trophoblastic-disease-market-6558